Global survey from the 2024 Adelphi Lupus Dse Specific Programme evaluated pt burden & MD/Pt Tx preferences: Efficacy & safety - top 2 MD-reported reasons for tx initiation OD, oral dosing-most preferred mode by MD & Pts Shared decision-making is key #ACR25 @RheumNow Abs1551 https://t.co/rmpCATCa78